Ganitumab ELISA Kit

Ganitumab (AMG-479) is a mAb against IGF-IR which also inhibits binding of both IGF-1 and IGF-2 ligands to IGF-IR. The therapeutic value of AMG-479 was evaluated in several preclinical settings including androgen-dependent prostate cancer, and combined with androgen-deprivation therapy. Ganitumab was found to be most potent against VCaP xenografts when it was used in combination with complete androgen-deprivation therapy. After 4 weeks of treatment, tumor volume was reduced by 72% and growth suppression was maintained over 16 weeks of treatment. These findings suggested that the use of ganitumab in conjunction with androgen-deprivation therapy may be beneficial in the treatment of prostate cancer.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.